Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 130,016	$ 43,073	$ 22,042
Costs and expenses:
Cost of revenue (excluding depreciation and amortization)	77,488	20,597	8,108
Research and development	305,705	136,827	92,321
Sales and marketing	53,447	28,395	18,270
General and administrative	245,087	71,055	50,722
Depreciation and amortization	82,004	18,654	10,375
Total operating costs and expenses	763,731	275,528	179,796
Loss from operations	(633,715)	(232,455)	(157,754)
Gain (loss) on change in fair value of warrant liabilities	66,710	(117,107)	(19,206)
Interest income, net	55,997	18,249	19,322
Offering costs associated with warrants	(45,714)	0	0
Other income (expense), net	29	(275)	(85)
Total net loss before income taxes	(556,693)	(331,588)	(157,723)
Income tax benefit (expense)	44,572	(59)	(48)
Net loss	(512,121)	(331,647)	(157,771)
Net loss attributable to noncontrolling interests	(1,743)	0	0
Net loss attributable to IonQ, Inc.	$ (510,378)	$ (331,647)	$ (157,771)
Net loss per share attributable to IonQ, Inc. common stockholders-basic	$ (1.82)	$ (1.56)	$ (0.78)
Net loss per share attributable to IonQ, Inc. common stockholders-diluted	$ (1.82)	$ (1.56)	$ (0.78)
Weighted average shares used in computing net loss per share attributable to IonQ, Inc. common stockholders-basic	280,345,046	213,029,365	202,576,492
Weighted average shares used in computing net loss per share attributable to IonQ, Inc. common stockholders-diluted	280,345,046	213,029,365	202,576,492

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (512,121)	$ (331,647)	$ (157,771)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	82,004	18,654	10,375
Stock-based compensation	312,032	106,878	69,743
(Gain) loss on change in fair value of warrant liabilities	(66,710)	117,107	19,206
Offering costs associated with warrants	45,714	0	0
Deferred income taxes	(44,868)	0	0
Amortization of premiums and accretion of discounts on available-for-sale securities	(8,323)	(8,804)	(9,746)
Other, net	18,366	5,323	1,994
Changes in operating assets and liabilities:
Accounts receivable	(37,667)	1,609	(8,175)
Prepaid expenses and other current assets	(72,171)	(15,200)	(14,413)
Accounts payable	(7,636)	(601)	2,188
Accrued expenses and other current liabilities	7,382	(411)	3,319
Unearned revenue	9,285	(1,752)	2,604
Other assets and liabilities	(8,474)	3,161	1,865
Net cash provided by (used in) operating activities	(283,187)	(105,683)	(78,811)
Cash flows from investing activities:
Purchases of property and equipment	(16,417)	(17,992)	(13,703)
Purchases of available-for-sale securities	(2,669,300)	(296,329)	(298,445)
Maturities of available-for-sale securities	682,830	418,082	386,760
Purchases of privately-held securities	(88,500)	0	0
Businesses acquired, net of cash paid and acquired	523	(15,454)	0
Other investing, net	(4,224)	(5,577)	(5,846)
Net cash provided by (used in) investing activities	(2,095,088)	82,730	68,766
Cash flows from financing activities:
Proceeds from Issuance of Common Stock	3,312,541	0	0
Proceeds from stock options exercised	26,744	8,012	1,954
Proceeds from warrants exercised	11,436	33,437	37
Other financing, net	7,881	238	(230)
Net cash provided by (used in) financing activities	3,358,602	41,687	1,761
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	581	25	(2)
Net change in cash, cash equivalents and restricted cash	980,908	18,759	(8,286)
Cash, cash equivalents and restricted cash at the beginning of the period	56,840	38,081	46,367
Cash, cash equivalents and restricted cash at the end of the period	1,037,748	56,840	38,081
Supplemental disclosures of non-cash investing and financing transactions
Property and equipment purchases in accounts payable and accrued expenses	1,278	1,060	773
Operating lease right-of-use assets subject to lease liability	0	6,129	2,380
Noncash reclassification of warrant liabilities to equity upon exercise	532,399	69,423	20
Bonus settled in restricted stock units	6,969	11,443	3,923
Equity issued for acquisitions	2,588,053	0	0
Equity issued for intangible assets	48,084	0	0
Equity issued for research and development arrangement	$ 68,691	$ 0	$ 0

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 1,030,865	$ 54,393
Short-term investments	1,361,291	285,896
Accounts receivable, net	66,532	10,188
Prepaid expenses and other current assets	127,751	28,325
Total current assets	2,586,439	378,802
Long-term investments	944,643	23,545
Property and equipment, net	120,145	52,761
Operating lease right-of-use assets	22,724	9,470
Intangible assets, net	767,432	29,469
Goodwill	1,963,584	9,904
Other noncurrent assets	165,391	4,437
Total Assets	6,570,358	508,388
Current liabilities:
Accounts payable	26,138	5,230
Accrued expenses and other current liabilities	89,721	16,811
Current portion of operating lease liabilities	8,850	3,366
Unearned revenue	42,116	10,678
Total current liabilities	166,825	36,085
Operating lease liabilities, net of current portion	21,171	14,359
Unearned revenue, net of current portion	1,921	0
Warrant liabilities	2,471,577	70,688
Other noncurrent liabilities	95,172	3,394
Total liabilities	2,756,666	124,526
Commitments and contingencies (see Note 11)
Stockholders' equity:
Common stock $0.0001 par value; 1,000,000,000 shares authorized; 362,592,722 and 221,919,191 shares outstanding as of December 31, 2025 and December 31, 2024, respectively	36	22
Additional paid-in capital	5,006,250	1,067,403
Accumulated deficit	(1,194,098)	(683,720)
Accumulated other comprehensive income (loss)	(12,671)	157
Total IonQ, Inc. stockholders' equity	3,799,517	383,862
Noncontrolling interests	14,175	0
Total stockholders' equity	3,813,692	383,862
Total Liabilities and Stockholders' Equity	$ 6,570,358	$ 508,388